Analysts Expect Leap Therapeutics, Inc. (LPTX) to Announce ($0.50) Earnings Per Share
Leap Therapeutics, Inc. (NASDAQ:LPTX) has received an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and one has given a strong buy recommendation to the company.
Brokerages have set a twelve-month consensus price target of $15.50 for the company and are forecasting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 104 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Leap Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd.
An institutional investor recently bought a new position in Leap Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned 0.48% of Leap Therapeutics at the end of the most recent quarter. 0.88% of the stock is owned by institutional investors and hedge funds.
Shares of Leap Therapeutics (NASDAQ LPTX) traded down 10.01% during midday trading on Thursday, reaching $6.43. 17,690 shares of the company’s stock traded hands. The stock’s market cap is $60.39 million. The stock has a 50 day moving average of $6.73 and a 200-day moving average of $7.28. Leap Therapeutics has a 52-week low of $5.40 and a 52-week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings data on Friday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.53. On average, equities research analysts expect that Leap Therapeutics will post ($3.36) EPS for the current year.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.